Molecular Templates, Inc., a clinical stage oncology company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed/refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. The company also develops MT-4019, engineered toxin body targeting CD38; and TAK-169 targeting CD38. It has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma. Molecular Templates, Inc. is headquartered in Austin, Texas.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [08/13/2019 10:29 PDT] Molecular Templates, Inc. (NASDAQ:MTEM), Down By 100.00% ($5.46) From $5.460 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [08/07/2019 08:01 PDT] MTEM Expected to Trade Down After Bearish Patterns Develop
• [07/29/2019 08:08 PDT] MTEM Expected to Trade Down Short Term
• [06/20/2019 10:30 PDT] Molecular Templates, Inc. (NASDAQ:MTEM), Up By 100.00% ($7.48) From $7.480 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions